Sarah J Nyante1, Mark E Sherman1, Ruth M Pfeiffer1, Amy Berrington de Gonzalez1, Louise A Brinton1, Erin J Aiello Bowles1, Robert N Hoover1, Andrew Glass1, Gretchen L Gierach2. 1. Division of Cancer Epidemiology and Genetics (SJN, MES, RMP, ABdG, LAB, RNH, GLG) and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Group Health Research Institute, Seattle, WA (EJAB); Kaiser Permanente Northwest Center for Health Research, Portland, OR (AG).Current affiliation: SJN is currently affiliated with the Radiology Department, University of North Carolina at Chapel Hill, Chapel Hill, NC. 2. Division of Cancer Epidemiology and Genetics (SJN, MES, RMP, ABdG, LAB, RNH, GLG) and Division of Cancer Prevention (MES), National Cancer Institute, Bethesda, MD; Group Health Research Institute, Seattle, WA (EJAB); Kaiser Permanente Northwest Center for Health Research, Portland, OR (AG).Current affiliation: SJN is currently affiliated with the Radiology Department, University of North Carolina at Chapel Hill, Chapel Hill, NC. gierachg@mail.nih.gov.
Abstract
BACKGROUND: A prior analysis of postmenopausal breast cancer patients linked a decline in mammographic density (MD) following the initiation of tamoxifen treatment with improved survival, but excluded premenopausal women, for whom tamoxifen is the primary anti-endocrine therapy. Therefore, we evaluated change in MD after tamoxifen and breast cancer death among patients age 32 to 87 years. METHODS: This case-control study included 349 estrogen receptor (ER)-positive breast cancer patients who were treated with tamoxifen at Kaiser Permanente Northwest (1990-2008): 97 who died from breast cancer (case patients) and 252 who did not (control patients), matched on age and year at diagnosis and disease stage. Percent MD in the unaffected breast was measured at baseline (mean six months before tamoxifen initiation) and follow-up (mean 12 months after initiation). Associations between change in MD and breast cancer death were estimated using conditional logistic regression. RESULTS: Patients in the highest tertile of MD decline had a lower risk of breast cancer death when compared with women in the lowest tertile (odds ratio [OR] = 0.44, 95% confidence interval [CI] = 0.22 to 0.88); results were similar after adjustment for baseline MD (OR = 0.49, 95% CI = 0.23 to 1.02). Reductions in death were observed only among patients in the middle and upper tertiles of baseline MD. Associations did not differ by age, tamoxifen use duration, estrogen and/or progestin use, body mass index, or receipt of chemotherapy or radiotherapy. CONCLUSION: These data suggest that younger and older ER-positive breast cancer patients who experience large reductions in MD following tamoxifen initiation have an improved prognosis. Published by Oxford University Press 2015.
BACKGROUND: A prior analysis of postmenopausal breast cancerpatients linked a decline in mammographic density (MD) following the initiation of tamoxifen treatment with improved survival, but excluded premenopausal women, for whom tamoxifen is the primary anti-endocrine therapy. Therefore, we evaluated change in MD after tamoxifen and breast cancer death among patients age 32 to 87 years. METHODS: This case-control study included 349 estrogen receptor (ER)-positive breast cancerpatients who were treated with tamoxifen at Kaiser Permanente Northwest (1990-2008): 97 who died from breast cancer (case patients) and 252 who did not (control patients), matched on age and year at diagnosis and disease stage. Percent MD in the unaffected breast was measured at baseline (mean six months before tamoxifen initiation) and follow-up (mean 12 months after initiation). Associations between change in MD and breast cancer death were estimated using conditional logistic regression. RESULTS:Patients in the highest tertile of MD decline had a lower risk of breast cancer death when compared with women in the lowest tertile (odds ratio [OR] = 0.44, 95% confidence interval [CI] = 0.22 to 0.88); results were similar after adjustment for baseline MD (OR = 0.49, 95% CI = 0.23 to 1.02). Reductions in death were observed only among patients in the middle and upper tertiles of baseline MD. Associations did not differ by age, tamoxifen use duration, estrogen and/or progestin use, body mass index, or receipt of chemotherapy or radiotherapy. CONCLUSION: These data suggest that younger and older ER-positive breast cancerpatients who experience large reductions in MD following tamoxifen initiation have an improved prognosis. Published by Oxford University Press 2015.
Authors: Jack Cuzick; Jane Warwick; Elizabeth Pinney; Stephen W Duffy; Simon Cawthorn; Anthony Howell; John F Forbes; Ruth M L Warren Journal: J Natl Cancer Inst Date: 2011-04-11 Impact factor: 13.506
Authors: Meredith M Regan; Brian Leyland-Jones; Mark Bouzyk; Olivia Pagani; Weining Tang; Roswitha Kammler; Patrizia Dell'orto; Maria Olivia Biasi; Beat Thürlimann; Maria B Lyng; Henrik J Ditzel; Patrick Neven; Marc Debled; Rudolf Maibach; Karen N Price; Richard D Gelber; Alan S Coates; Aron Goldhirsch; James M Rae; Giuseppe Viale Journal: J Natl Cancer Inst Date: 2012-03-06 Impact factor: 13.506
Authors: James M Rae; Meredith M Regan; Jacklyn N Thibert; Christina Gersch; Dafydd Thomas; Brian Leyland-Jones; Giuseppe Viale; Lajos Pusztai; Daniel F Hayes; Todd Skaar; Catherine Van Poznak Journal: J Natl Cancer Inst Date: 2013-08-19 Impact factor: 13.506
Authors: Jingmei Li; Keith Humphreys; Louise Eriksson; Gustaf Edgren; Kamila Czene; Per Hall Journal: J Clin Oncol Date: 2013-04-22 Impact factor: 44.544
Authors: Gretchen L Gierach; Laura Ichikawa; Karla Kerlikowske; Louise A Brinton; Ghada N Farhat; Pamela M Vacek; Donald L Weaver; Catherine Schairer; Stephen H Taplin; Mark E Sherman Journal: J Natl Cancer Inst Date: 2012-08-21 Impact factor: 13.506
Authors: Natalie J Engmann; Christopher G Scott; Matthew R Jensen; Lin Ma; Kathleen R Brandt; Amir Pasha Mahmoudzadeh; Serghei Malkov; Dana H Whaley; Carrie B Hruska; Fang Fang Wu; Stacey J Winham; Diana L Miglioretti; Aaron D Norman; John J Heine; John Shepherd; V Shane Pankratz; Celine M Vachon; Karla Kerlikowske Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-02-01 Impact factor: 4.254
Authors: Michael S Shawky; Cecilia W Huo; Kara Britt; Erik W Thompson; Michael A Henderson; Andrew Redfern Journal: Breast Cancer Res Treat Date: 2019-06-08 Impact factor: 4.872
Authors: Rafael Alvarez; Elika Ridelman; Natalie Rizk; Morgan S White; Chuan Zhou; Heang-Ping Chan; Oliver A Varban; Mark A Helvie; Randy J Seeley Journal: Surg Obes Relat Dis Date: 2018-08-01 Impact factor: 4.734
Authors: Maeve Mullooly; Ruth M Pfeiffer; Sarah J Nyante; Brandy M Heckman-Stoddard; Marjorie Perloff; Ismail Jatoi; Louise A Brinton; Erin J Aiello Bowles; Robert N Hoover; Andrew Glass; Amy Berrington de Gonzalez; Mark E Sherman; Gretchen L Gierach Journal: J Clin Oncol Date: 2016-03-28 Impact factor: 44.544
Authors: Antonis Antoniou; Hoda Anton-Culver; Alexander Borowsky; Mireille Broeders; Jennifer Brooks; Anna Chiarelli; Jocelyne Chiquette; Jack Cuzick; Suzette Delaloge; Peter Devilee; Michael Dorval; Douglas Easton; Andrea Eisen; Martin Eklund; Laurence Eloy; Laura Esserman; Montserrat Garcia-Closas; David Goldgar; Per Hall; Bartha Maria Knoppers; Peter Kraft; Andrea La Croix; Lisa Madalensky; Nasim Mavaddat; Nicole Mittman; Hermann Nabi; Olufunmilayo Olopade; Nora Pashayan; Marjanka Schmidt; Yiwey Shieh; Jacques Simard; Allison Stover-Fiscallini; Jeffrey A Tice; Laura Van't Veer; Neil Wenger; Michael Wolfson; Christina Yau; Elad Ziv Journal: Hum Genet Date: 2019-02-27 Impact factor: 4.132
Authors: Kathleen R Brandt; Christopher G Scott; Lin Ma; Amir P Mahmoudzadeh; Matthew R Jensen; Dana H Whaley; Fang Fang Wu; Serghei Malkov; Carrie B Hruska; Aaron D Norman; John Heine; John Shepherd; V Shane Pankratz; Karla Kerlikowske; Celine M Vachon Journal: Radiology Date: 2015-12-22 Impact factor: 11.105
Authors: Zeina G Khodr; Mark A Sak; Ruth M Pfeiffer; Nebojsa Duric; Peter Littrup; Lisa Bey-Knight; Haythem Ali; Patricia Vallieres; Mark E Sherman; Gretchen L Gierach Journal: Med Phys Date: 2015-10 Impact factor: 4.071
Authors: Michael A Pinkert; Lonie R Salkowski; Patricia J Keely; Timothy J Hall; Walter F Block; Kevin W Eliceiri Journal: J Med Imaging (Bellingham) Date: 2018-01-22